AU2015295120B2 - [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases - Google Patents

[1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases Download PDF

Info

Publication number
AU2015295120B2
AU2015295120B2 AU2015295120A AU2015295120A AU2015295120B2 AU 2015295120 B2 AU2015295120 B2 AU 2015295120B2 AU 2015295120 A AU2015295120 A AU 2015295120A AU 2015295120 A AU2015295120 A AU 2015295120A AU 2015295120 B2 AU2015295120 B2 AU 2015295120B2
Authority
AU
Australia
Prior art keywords
compound
crystal
hydroxy
pct
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015295120A
Other languages
English (en)
Other versions
AU2015295120A1 (en
AU2015295120A8 (en
Inventor
Robert Hugh Bradbury
Zoe Ann COTTER
Steven Christopher GLOSSOP
Arshed MAHMOOD
James Francis Mccabe
Alfred Arthur Rabow
Michael James Waring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2015295120A1 publication Critical patent/AU2015295120A1/en
Publication of AU2015295120A8 publication Critical patent/AU2015295120A8/en
Application granted granted Critical
Publication of AU2015295120B2 publication Critical patent/AU2015295120B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • EFIXED CONSTRUCTIONS
    • E21EARTH OR ROCK DRILLING; MINING
    • E21BEARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00Special methods or apparatus for drilling
    • E21B7/04Directional drilling
    • E21B7/06Deflecting the direction of boreholes
    • EFIXED CONSTRUCTIONS
    • E21EARTH OR ROCK DRILLING; MINING
    • E21BEARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00Special methods or apparatus for drilling
    • E21B7/04Directional drilling
    • E21B7/06Deflecting the direction of boreholes
    • E21B7/062Deflecting the direction of boreholes the tool shaft rotating inside a non-rotating guide travelling with the shaft
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mining & Mineral Resources (AREA)
  • Geology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Geochemistry & Mineralogy (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Fluid Mechanics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2015295120A 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases Ceased AU2015295120B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029676P 2014-07-28 2014-07-28
US62/029,676 2014-07-28
PCT/GB2015/052143 WO2016016618A1 (en) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases

Publications (3)

Publication Number Publication Date
AU2015295120A1 AU2015295120A1 (en) 2017-02-02
AU2015295120A8 AU2015295120A8 (en) 2017-02-09
AU2015295120B2 true AU2015295120B2 (en) 2018-02-01

Family

ID=53761420

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015295120A Ceased AU2015295120B2 (en) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases

Country Status (37)

Country Link
US (5) US9944650B2 (OSRAM)
EP (1) EP3174881B1 (OSRAM)
JP (1) JP6592503B2 (OSRAM)
KR (1) KR20170033427A (OSRAM)
CN (1) CN106536524B (OSRAM)
AP (1) AP2017009700A0 (OSRAM)
AU (1) AU2015295120B2 (OSRAM)
BR (1) BR112017001160A2 (OSRAM)
CA (2) CA3185741A1 (OSRAM)
CL (1) CL2017000223A1 (OSRAM)
CO (1) CO2017001918A2 (OSRAM)
CY (1) CY1120602T1 (OSRAM)
DK (1) DK3174881T3 (OSRAM)
DO (1) DOP2017000018A (OSRAM)
EA (1) EA032654B9 (OSRAM)
ES (1) ES2670444T3 (OSRAM)
GT (1) GT201700016A (OSRAM)
HR (1) HRP20180788T1 (OSRAM)
HU (1) HUE037571T2 (OSRAM)
IL (1) IL250104B (OSRAM)
LT (1) LT3174881T (OSRAM)
MX (1) MX374539B (OSRAM)
MY (1) MY187251A (OSRAM)
NI (1) NI201700006A (OSRAM)
NO (2) NO2719005T3 (OSRAM)
PE (1) PE20170527A1 (OSRAM)
PH (1) PH12017500159B1 (OSRAM)
PL (1) PL3174881T3 (OSRAM)
PT (1) PT3174881T (OSRAM)
RS (1) RS57242B1 (OSRAM)
SG (1) SG11201700419SA (OSRAM)
SI (1) SI3174881T1 (OSRAM)
SM (1) SMT201800260T1 (OSRAM)
SV (1) SV2017005368A (OSRAM)
TN (1) TN2017000018A1 (OSRAM)
WO (1) WO2016016618A1 (OSRAM)
ZA (1) ZA201701207B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2719005T3 (OSRAM) * 2014-07-28 2018-01-20
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑并哒嗪类衍生物在医药领域的应用
TWI816880B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥(上海)股份有限公司 治療前列腺癌之組合療法
BR112022007210A2 (pt) 2019-10-14 2022-07-05 Astrazeneca Ab Terapia de combinação para tratar malignidade hematológica
IL294399A (en) 2020-01-09 2022-08-01 Astrazeneca Ab Combination therapy for treating cancer
CN113143930B (zh) * 2021-04-08 2023-05-30 深圳湾实验室 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092371A1 (en) * 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
WO2010131022A1 (en) * 2009-05-11 2010-11-18 Astrazeneca Ab [1,2,4] triazolo [4,3-b] pyridazines as ligands of the androgen receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525065D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
RU2008127263A (ru) 2005-12-08 2010-01-20 Новартис АГ (CH) ПИРАЗОЛ [1,5-a] ПИРИДИН-3-КАРБОНОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ EphB-И VEGFR2-КИНАЗЫ
CN101952286A (zh) 2007-12-21 2011-01-19 阿斯利康(瑞典)有限公司 用于治疗和雄激素受体有关的病症的双环衍生物
RS53179B (sr) 2009-11-05 2014-06-30 Glaxosmithkline Llc Benzodiazepinski inhibitor bromodomena
US9328117B2 (en) * 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422290B2 (en) * 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
NO2719005T3 (OSRAM) * 2014-07-28 2018-01-20

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092371A1 (en) * 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
WO2010131022A1 (en) * 2009-05-11 2010-11-18 Astrazeneca Ab [1,2,4] triazolo [4,3-b] pyridazines as ligands of the androgen receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRADBURY ROBERT H ET AL, "Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, vol. 23, no. 7, pages 1945 - 1948 *
JADAV PRADIP ET AL, "Design, synthesis and biological evaluation of novel aminomethyl-piperidones based DPP-IV inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, vol. 24, no. 8, pages 1918 - 1922 *

Also Published As

Publication number Publication date
EP3174881B1 (en) 2018-03-28
SV2017005368A (es) 2017-05-12
TN2017000018A1 (en) 2018-07-04
US20230035133A1 (en) 2023-02-02
NO2719005T3 (OSRAM) 2018-01-20
NI201700006A (es) 2017-08-25
AU2015295120A1 (en) 2017-02-02
US20210107905A1 (en) 2021-04-15
AU2015295120A8 (en) 2017-02-09
MX2017001218A (es) 2017-05-01
PE20170527A1 (es) 2017-05-24
MY187251A (en) 2021-09-15
DOP2017000018A (es) 2017-03-15
BR112017001160A2 (pt) 2017-11-14
KR20170033427A (ko) 2017-03-24
EP3174881A1 (en) 2017-06-07
PL3174881T3 (pl) 2018-08-31
US20170210747A1 (en) 2017-07-27
CY1120602T1 (el) 2019-12-11
US10407432B2 (en) 2019-09-10
CO2017001918A2 (es) 2017-05-10
JP6592503B2 (ja) 2019-10-16
CA3185741A1 (en) 2016-02-04
CA2956421A1 (en) 2016-02-04
CL2017000223A1 (es) 2017-08-25
US11407755B2 (en) 2022-08-09
EA201790179A1 (ru) 2017-07-31
IL250104B (en) 2018-10-31
RS57242B1 (sr) 2018-07-31
US10766905B2 (en) 2020-09-08
IL250104A0 (en) 2017-03-30
NO3174881T3 (OSRAM) 2018-08-25
PT3174881T (pt) 2018-05-25
HRP20180788T1 (hr) 2018-06-29
MX374539B (es) 2025-03-06
LT3174881T (lt) 2018-06-11
ZA201701207B (en) 2018-12-19
US20200055861A1 (en) 2020-02-20
EA032654B9 (ru) 2019-07-31
CN106536524A (zh) 2017-03-22
SG11201700419SA (en) 2017-02-27
SMT201800260T1 (it) 2018-07-17
CN106536524B (zh) 2019-11-15
DK3174881T3 (en) 2018-06-06
HUE037571T2 (hu) 2018-09-28
US20180230158A1 (en) 2018-08-16
PH12017500159A1 (en) 2017-07-10
GT201700016A (es) 2018-12-19
ES2670444T3 (es) 2018-05-30
AP2017009700A0 (en) 2017-01-31
CA2956421C (en) 2023-03-14
WO2016016618A1 (en) 2016-02-04
PH12017500159B1 (en) 2020-12-09
EA032654B1 (ru) 2019-06-28
US9944650B2 (en) 2018-04-17
SI3174881T1 (en) 2018-06-29
JP2017522338A (ja) 2017-08-10

Similar Documents

Publication Publication Date Title
US20230035133A1 (en) [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases
US11274098B2 (en) Tricyclic compounds for use in treatment of proliferative disorders
AU2010212590B2 (en) Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
JP2011526586A (ja) Hdac阻害薬としての複素環誘導体
EP2809671B1 (en) Imidazo [4, 5 - b]pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
WO2017194632A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EA026655B1 (ru) 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
CA3099579A1 (en) Triazolopyrimidine compounds and their use in treating cancer
US20100292222A1 (en) Chemical compounds 751
WO2024233742A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
CA3119882A1 (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
HK1235059B (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
HK1235059A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
WO2025055868A1 (zh) 抑制cdk4/6与细胞周期蛋白d的蛋白-蛋白相互作用的化合物
HK1204610B (en) Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 31 , NO 4 , PAGE(S) 533 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ASTRAZENECA AB, APPLICATION NO. 2015295120, UNDER INID (54) CORRECT THE TITLE TO READ (1,2,4)TRIAZOLO(4,3-B)PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired